Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaSTAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
/in Immunogenic Cell Death, International Publications, Malignant Melanoma, Newcastle Disease VirusPhase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
/in Colorectal Cancer, Gastric Cancer, International Publications, MicronutrientsAdjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaWhole-body hyperthermia in combination with systemic therapy in advanced solid malignancies
/in Hyperthermia, International PublicationsTargeting cancer vulnerabilities with high-dose vitamin C
/in International Publications, MicronutrientsA new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model
/in Dendritic Cells, International PublicationsOncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease VirusThe Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review
/in International Publications, Micronutrients
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer